Evaluation of the Antibody Persistence Beyond Five Years After Immunization With MenFiveTM (NmCV-5), a Pentavalent Meningococcal ACYWX Conjugate Vaccine

ConditionMeningoccocal Disease

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age7-36

SponsorSerum Institute of India Pvt. Ltd.

About this trial

This study will measure immune persistence of the NmCV-5 more than 5 years after a single dose vaccination in participants 2-29 years of age in Mali and The Gambia.

Eligibility criteria

Qualifiers

Written informed consent and assent (if applicable)

Disqualifiers

Current or previous, confirmed disease caused by Neisseria meningitidis at any given time since meningococcal vaccination

Any condition or criteria that in the opinion of the investigator might compromise the well-being of the participant or the compliance with study procedures or interfere with the outcome of the study

Trial design

Treatments tested in this trial

Not listed

Trial groups

450 Participants

are grouped into 2 trial groups

Sponsors and collaborators

Serum Institute of India Pvt. Ltd.

Lead sponsor

Source ClinicalTrials.gov